Research map: Preclinical Ocular Pharmacokinetics and Efficacy of Novel Tivozanib Eye Drops for Neovascular Age-Related Macular Degeneration

Back to the article

Papers in this map

  1. Ranibizumab for Neovascular Age-Related Macular Degeneration · Philip J. Rosenfeld · 2006 · 5929 citations · Cited by this paper
  2. Genomic Copy Number Variants Associated With Strabismus and Amblyopia in the All of Us Research Program · 2026 · Related
  3. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis · Wan Ling Wong · 2014 · 5457 citations · Cited by this paper
  4. Z-Nucleic Acids: A Regulator of Macrophage PANoptosis and Fungal Biofilm in Fungal Keratitis · 2026 · Related
  5. Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration · David M. Brown · 2006 · 3534 citations · Cited by this paper
  6. New Guidelines for Ophthalmic Genetic Studies · 2026 · Related
  7. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration · Jeffrey S. Heier · 2012 · 2521 citations · Cited by this paper
  8. Impact of Continuous Positive Airway Pressure Treatment on Retinal Vasculature in Obstructive Sleep Apnea: A 7-Year Follow-Up · 2026 · Related
  9. Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration · Daniel Francis Martin · 2012 · 1726 citations · Cited by this paper
  10. Loss of ATRAID in Late-Onset, Non-Syndromic Retinitis Pigmentosa · 2026 · Related
  11. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration · Pravin U. Dugel · 2019 · 938 citations · Cited by this paper
  12. Identification of a Duplication in the RP17 Locus in an Individual With Pathogenic CEP290 Variants: Implications for RP17 Variant Classification · 2026 · Related
  13. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials · Jeffrey S Heier · 2022 · 788 citations · Cited by this paper
  14. Compartment-Specific Associations of GDF15 With Intraocular Cytokines in Patients With Idiopathic Epiretinal Membrane · 2026 · Related
  15. State of the art of nanocrystals – Special features, production, nanotoxicology aspects and intracellular delivery · Rainer Helmut Müller · 2011 · 702 citations · Cited by this paper
  16. AAV8-Mediated Retinal PD-L1 Gene Transfer Attenuates Experimental Autoimmune Uveitis by Restoring Local Immune Tolerance · 2026 · Related
  17. 2002 Global update of available data on visual impairment: a compilation of population-based prevalence studies · Donatella Pascolini · 2004 · 529 citations · Cited by this paper
  18. Association of IL-8 and IL-18 Expression With Histone-Associated NETosis in Aqueous-Deficient and Evaporative Dry Eye Disease · 2026 · Related
  19. Age-related macular degeneration · Robyn H. Guymer · 2023 · 498 citations · Cited by this paper
  20. Topical and systemic drug delivery to the posterior segments · Pamela Hughes · 2005 · 402 citations · Cited by this paper
  21. Overexpression of Vascular Endothelial Growth Factor (VEGF) in the Retinal Pigment Epithelium Leads to the Development of Choroidal Neovascularization · Katrina Spilsbury · 2000 · 399 citations · Cited by this paper
  22. KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular Properties · Kazuhide Nakamura · 2006 · 211 citations · Cited by this paper
  23. Pazopanib: A novel multitargeted tyrosine kinase inhibitor · Guru Sonpavde · 2007 · 203 citations · Cited by this paper
  24. Clinical update: new treatments for age-related macular degeneration · Tien Yin Wong · 2007 · 168 citations · Cited by this paper
  25. Neovascular Macular Degeneration: A Review of Etiology, Risk Factors, and Recent Advances in Research and Therapy · Arunbalaji Pugazhendhi · 2021 · 143 citations · Cited by this paper
  26. Topical Drug Delivery to the Posterior Segment of the Eye: Addressing the Challenge of Preclinical to Clinical Translation · Gerard A. Rodrigues · 2018 · 127 citations · Cited by this paper
  27. Implications of melanin binding in ocular drug delivery · Anna‐Kaisa Rimpelä · 2017 · 120 citations · Cited by this paper
  28. Innovative therapies for neovascular age-related macular degeneration · Hasenin Al-khersan · 2019 · 114 citations · Cited by this paper
  29. Topical Drug Delivery to the Posterior Segment of the Eye · Marina Löscher · 2022 · 108 citations · Cited by this paper
  30. Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration · Rehan M. Hussain · 2021 · 86 citations · Cited by this paper
  31. Intraocular distribution of melanin in human, monkey, rabbit, minipig and dog eyes · Chandrasekar Durairaj · 2012 · 84 citations · Cited by this paper
  32. Clinical Evaluation of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections in Subjects with Neovascular Age-Related Macular Degeneration · Karl G. Csaky · 2014 · 76 citations · Cited by this paper
  33. The Developing Regorafenib Eye drops for neovascular Age‐related Macular degeneration (DREAM) study: an open‐label phase II trial · Antonia Maria Joussen · 2018 · 63 citations · Cited by this paper
  34. How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches · Vibhuti Agrahari · 2016 · 59 citations · Cited by this paper
  35. Emerging treatments for wet age-related macular degeneration · Adiel G. Smith · 2014 · 54 citations · Cited by this paper
  36. Prevention of the Onset of Age-Related Macular Degeneration · Emiliano Di Carlo · 2021 · 50 citations · Cited by this paper
  37. FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma · Elaine Chang · 2021 · 47 citations · Cited by this paper
  38. The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration · Christopher M. Adams · 2018 · 42 citations · Cited by this paper
  39. Species differences in ocular pharmacokinetics and pharmacological activities of regorafenib and pazopanib eye‐drops among rats, rabbits and monkeys · Shinya Horita · 2019 · 34 citations · Cited by this paper

Source: OpenAlex (CC0)